Founded in 2007, Klea Holding is a group focused on acquiring, developing and digitizing companies in various sectors to maximize their growth and value. Through its "scaling industries of the future" identity, Klea Holding draws on its successful experience in developing Smart Salem, the first network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, its joint venture Smart Health, dedicated to the roll-out of digital medical testing centres in Saudi Arabia; and Klea Pharmaceuticals, a subsidiary dedicated to the commercialisation of a portfolio of licensed medicines in the Middle East and Africa.

Employees

Sector

Healthcare Facilities & Services

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed London S.E. Other stock markets 11:35:38 2018-05-22 EDT			5-day change	1st Jan Change
0.4170 ^EUR	-0.48%		-.--%	-

06-11	Klea Holding SA Announces the Launch of Its New Subsidiary, Klea Pharmaceuticals	CI
06-11	Klea Launches Medicine Distribution Business for Middle East, Africa	MT

Market Cap	57.16M 65.07M 52.67M 49.31M 92.38M 6.16B 93.94M 632M 245M 3.02B 244M 239M 10.51B	P/E 2024	44.3x	P/E 2025	31.3x
Enterprise Value	57.29M 65.21M 52.79M 49.41M 92.58M 6.18B 94.14M 634M 245M 3.03B 245M 240M 10.53B	EV / Sales 2024	3.3x	EV / Sales 2025	3.04x
Free-Float	99.83%	Yield 2024 *	-	Yield 2025	-

06-11	Klea Holding SA Announces the Launch of Its New Subsidiary, Klea Pharmaceuticals	CI
06-11	Klea Launches Medicine Distribution Business for Middle East, Africa	MT
06-11	Klea Holding announces the launch of its new subsidiary
04-23	Klea Holding SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-01	Klea Holding Establishes Klea Pharmaceuticals and Expands Healthcare Operations in Middle East and Africa	CI
03-31	Klea Holding SA acquired New Licences and Pharmaceutical Assets for AED 8.5 million.	CI
01-19	Klea Holding Increases Annual Revenue by 28%
01-19	Klea Holding SA Reports Unaudited Consolidated Sales Results for the Year Ended December 31, 2025	CI
01-19	Klea Holding SA to Open First Digital Medical Centre in Saudi Arabia in March/April 2026	CI
25-10-27	Klea Holding Strengthens Its Presence in Dubai with Its First Strategic Real Estate Investment in the Lumena Alta Project	CI
25-10-27	Klea Holding Buys Office Space at Skyscraper Project in Dubai	MT
25-09-18	Klea Holding SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-18	Klea Holding SA commences an Equity Buyback Plan for 30,751,431 shares, representing 10% of its issued share capital for ?46.13 million, under the authorization approved on June 10, 2025.	CI

06-11	Klea Holding : Klea Pharmaceuticals launch its business with a strong partner	AT
04-23	Klea : reports record results in 2025 and demonstrates remarkable resilience in Q1 2026	PU
04-23	Klea Holding : Klea Holding reports record results in 2025 and demonstrates remarkable resilience in Q1 2026	AT
04-01	Klea Holding : Klea Holding is accelerating its diversification into the healthcare sector with the creation of Klea Pharmaceuticals	AT
01-19	Klea Holding : Klea Holding reports profitable growth of 34% in turnover in 2025 at constant exchange rates	AT

Visiomed Group Stock London S.E.

Stocks

0D13

FR0013481835

Healthcare Facilities & Services

Valuation: Visiomed Group

Latest news : Visiomed Group

Analysts' recommendations: Visiomed Group

Press Releases: Visiomed Group

News in other languages: Visiomed Group

Quotes and Performance

Managers and Directors: Visiomed Group

Other Healthcare Facilities & Services

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Klea Holding : Déclaration des transactions sur actions propres
06-11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
06-11	Klea Holding annonce le démarrage de sa nouvelle filiale
06-11	Une bonne grosse purge avant SpaceX
06-11	Klea Holding : Klea Pharmaceuticals annonce le démarrage de son activité avec un puissant partenaire

Manager	Title	Age	Since
Clement Pacaud CEO	Chief Executive Officer	36	2024-01-21
Jérôme Fabreguettes-Leib IRC	Investor Relations Contact	-	-
Thomas Picquette CEO	Chief Executive Officer	-	2022-03-31

Director	Title	Age	Since
Guillaume Bremond CHM	Chairman	-	-
Anne Gaignard BRD	Director/Board Member	-	2022-03-31
Paul Amsellem BRD	Director/Board Member	51	2023-06-13

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VISIOMED GROUP	-0.48%	-.--%	-	-	65.07M
CVS HEALTH CORPORATION	+0.27%	+0.84%	+52.03%	+45.93%	130B
HCA HEALTHCARE, INC.	+2.63%	-2.52%	+2.17%	+30.98%	85.83B
FRESENIUS SE & CO. KGAA	+0.91%	+2.91%	-4.48%	+58.40%	25.58B
QUEST DIAGNOSTICS INCORPORATED	+1.86%	-1.92%	+9.72%	+39.36%	21.83B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.47%	-2.61%	-15.07%	-25.58%	19.86B
TENET HEALTHCARE CORPORATION	+1.19%	-1.46%	+6.95%	+131.30%	15.58B
REDE D'OR SÃO LUIZ S.A.	+1.51%	+0.76%	-1.04%	+2.91%	14.56B
DAVITA INC.	+0.60%	+0.93%	+54.71%	+115.83%	13.54B
FRESENIUS MEDICAL CARE AG	+0.73%	+1.27%	-11.18%	-7.34%	12.7B
Average	+0.74%	-0.19%	+10.42%	+43.53%	37.68B
Weighted average by Cap.	+1.02%	-0.32%	+21.88%	+41.35%

	2024	2025
Net sales	17.26M 19.65M 15.9M 14.89M 27.89M 1.86B 28.36M 191M 73.92M 913M 73.76M 72.17M 3.17B	22.17M 25.23M 20.42M 19.12M 35.82M 2.39B 36.43M 245M 94.93M 1.17B 94.72M 92.68M 4.08B
Net income	1.4M 1.6M 1.29M 1.21M 2.27M 152M 2.31M 15.55M 6.02M 74.33M 6M 5.87M 258M	2.28M 2.6M 2.1M 1.97M 3.69M 246M 3.75M 25.24M 9.77M 121M 9.75M 9.54M 419M
Net Debt	2.58M 2.93M 2.37M 2.22M 4.16M 278M 4.23M 28.49M 11.03M 136M 11M 10.77M 474M	125K 142K 115K 108K 202K 13.48M 205K 1.38M 535K 6.61M 534K 523K 22.99M